HOTH Share Price | Hoth Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Hoth Therapeutics, Inc.?

Market Cap: As of Jun 18, Hoth Therapeutics, Inc. has a market capitalization of 17.17 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Hoth Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -9.62 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 6.88 million and total assets of 7.71 million.

Q: What does Hoth Therapeutics, Inc. do?

Overview: Hoth Therapeutics, Inc. is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market-cap: USD 17.17 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.98 Return on Equity: -83.39% Price to Book: 1.49Contact Details: Address: 701 S Carson St Ste 200, NEW YORK NY: 10020-2003 Tel: 1 551 5782261 Website: https://hoththerapeutics.com/

Q: Is Hoth Therapeutics, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Hoth Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the Bollinger Bands and daily moving averages indicate a bullish stance. However, the monthly RSI is bearish, which introduces some caution. The overall strength of the bullish trend is supported by the weekly KST and Dow Theory, both showing mild bullishness. In terms of performance, Hoth Therapeutics has significantly outperformed the S&P 500 over the past year with a return of 90.10% compared to the S&P 500's 17.14%, and it has also shown strong returns of 48.84% over the last month versus the S&P 500's 2.33%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

23.71 k

Shareholding (Sep 2025)

FII

0.82%

Held by 7 FIIs

DII

97.03%

Held by 2 DIIs

Promoter

0.00%

How big is Hoth Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Hoth Therapeutics, Inc. has a market capitalization of 17.17 million, with net sales of 0.00 million and a net profit of -9.62 million over the last four quarters. The company reported shareholder's funds of 6.88 million and total assets of 7.71 million as of Dec 24.

View full answer

What does Hoth Therapeutics, Inc. do?

22-Jun-2025

Hoth Therapeutics, Inc. is a micro-cap biopharmaceutical company focused on developing targeted therapeutics for conditions like atopic dermatitis. As of March 2025, it reported a net profit loss of $3 million and has a market cap of $17.17 million.

View full answer

Is Hoth Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Hoth Therapeutics, Inc. has shifted to a bullish trend supported by positive weekly indicators, despite a bearish monthly RSI, and has outperformed the S&P 500 with a 90.10% return over the past year.

View full answer

Compare Hoth Therapeutics, Inc. with Similar Stocks

Agile Therapeutics, Inc.PainReform Ltd.TRACON Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 16 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.95

Return on Equity

-147.46%

Price to Book

1.98

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-29.99%

6 Months

-9.93%

1 Year

-22.99%

2 Years

-74.33%

3 Years

-92.62%

4 Years

-98.07%

5 Years

-98.92%

Hoth Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-0.49%

EBIT to Interest (avg)

-9.47

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.98

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.50%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.49

EV to EBIT

-0.61

EV to EBITDA

-0.61

EV to Capital Employed

5.88

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-963.73%

ROE (Latest)

-83.39%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (2.15%)

Foreign Institutions

Held by 7 Foreign Institutions (0.82%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 37.14% vs -45.83% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.20",
          "val2": "-3.50",
          "chgp": "37.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-3.50",
          "chgp": "37.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -5.13% vs 31.58% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.20",
          "val2": "-7.70",
          "chgp": "-6.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.20",
          "val2": "-7.80",
          "chgp": "-5.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.20

-3.50

37.14%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.20

-3.50

37.14%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 37.14% vs -45.83% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-8.20

-7.70

-6.49%

Interest

0.00

Exceptional Items

-0.00

-0.20

100.00%

Consolidate Net Profit

-8.20

-7.80

-5.13%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -5.13% vs 31.58% in Dec 2023

All Annual Results

Company CV

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The Company is engaged in developing and commercializing the BioLexa Platform. BioLexa Platform is a proprietary, patented antimicrobial therapy. The BioLexa Platform traps all the zinc ions by adding a chelator called DTPA, which prevents Staph biofilm formation. It intends to explore the use of the BioLexa Platform for the treatment of atopic dermatitis, or eczema. It also focuses on exploring the use of the BioLexa Platform in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures.

Company Coordinates

Company Details

701 S Carson St Ste 200 , NEW YORK NY : 10020-2003

Tel: 1 551 5782261

https://hoththerapeutics.com/

Registrar Details

Hoth Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Hoth Therapeutics, Inc.?

Watch in Real-Time

What does Hoth Therapeutics, Inc. do?

Is Hoth Therapeutics, Inc. technically bullish or bearish?

Compare Hoth Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Hoth Therapeutics, Inc.

Company Coordinates